Meenakshi Venkatasubramanian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meenakshi Venkatasubramanian has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Aishwarya Kulkarni
Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
1 shared publication- Amit Verma
Department of Mathematics, Indian Institute of Technology Patna, Patna, India
1 shared publication Ariel Fromowitz
Department of Oncology, Blood Cancer Institute, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY 10461, USA
1 shared publication- Daniel T. Starczynowski
Department of Pediatrics, University of Cincinnati, Cincinnati, OH
1 shared publication - David Shechter
Department of Biochemistry, Albert Einstein College of Medicine, Bronx, USA
1 shared publication Davy Lee
Pacific Biosciences, Menlo Park, CA 94025, USA
1 shared publication
Latest Publications
- 7 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (797) , eadr1471
Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias
The role of splicing dysregulation in cancer is underscored by splicing factor mutations; however, its impact in the absence of such rare mutations remains poorly understood. Prompted by the finding that splicing uniquely resolved genetic subtypes of cancer, we developed an unsupervised computational workflow called OncoSplice to comprehensively define tumor molecular landscapes. In adult and pediatric acute myeloid leukemia (AML), OncoSplice identified the spectrum of driver genetics from splicing profiles alone, defined more than a dozen previously unreported molecular subtypes recurrent across AML cohorts, and discovered a dominant splicing subtype that partially phenocopies U2AF1 -mutant splicing. Although pediatric leukemias lack splicing factor mutations, this U2AF1 -like subtype similarly spanned pediatric and adult AML genetics and consistently predicted poor prognosis. Using long-read single-cell RNA sequencing, we confirmed that discovered U2AF1 -like splicing was shared across cell states, co-opted a healthy circadian gene program, was stable through relapse, and induced a leukemic stem cell program. Pharmacological inhibition of an implicated U2AF1 -like splicing regulator, PRMT5, rescued leukemia missplicing and inhibited leukemic cell growth. Finally, genetic deletion of IRAK4 , a common target of U2AF1 -like and PRMT5 treatment, blocked leukemia development in xenograft models and induced differentiation. This work suggests that broad splicing dysregulation, in the absence of select mutations, is a therapeutic target in heterogeneous leukemias.
- 7 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (797) , eadr1471
Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias
The role of splicing dysregulation in cancer is underscored by splicing factor mutations; however, its impact in the absence of such rare mutations remains poorly understood. Prompted by the finding that splicing uniquely resolved genetic subtypes of cancer, we developed an unsupervised computational workflow called OncoSplice to comprehensively define tumor molecular landscapes. In adult and pediatric acute myeloid leukemia (AML), OncoSplice identified the spectrum of driver genetics from splicing profiles alone, defined more than a dozen previously unreported molecular subtypes recurrent across AML cohorts, and discovered a dominant splicing subtype that partially phenocopies U2AF1 -mutant splicing. Although pediatric leukemias lack splicing factor mutations, this U2AF1 -like subtype similarly spanned pediatric and adult AML genetics and consistently predicted poor prognosis. Using long-read single-cell RNA sequencing, we confirmed that discovered U2AF1 -like splicing was shared across cell states, co-opted a healthy circadian gene program, was stable through relapse, and induced a leukemic stem cell program. Pharmacological inhibition of an implicated U2AF1 -like splicing regulator, PRMT5, rescued leukemia missplicing and inhibited leukemic cell growth. Finally, genetic deletion of IRAK4 , a common target of U2AF1 -like and PRMT5 treatment, blocked leukemia development in xenograft models and induced differentiation. This work suggests that broad splicing dysregulation, in the absence of select mutations, is a therapeutic target in heterogeneous leukemias.